Clinical trial
Phase II Study of Clofarabine in Pediatric Acute Myelogenous Leukemia (AML)…
NCT00042354 · Genzyme, a Sanofi Company, Industry · Completed
Key facts
| NCT number | NCT00042354 |
|---|---|
| Title | Phase II Study of Clofarabine in Pediatric Acute Myelogenous Leukemia (AML) Patients |
| Official title | A Phase II, Open Label Study of Clofarabine in Pediatric Patients With Refractory or Relapsed Acute Myelogenous Leukemia |
| Lead sponsor | Genzyme, a Sanofi Company, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Leukemia, Myelocytic, Acute, Pediatric |
| Intervention type | Drug |
| Interventions | clofarabine (IV formulation) |
| Enrollment | 40 |
| Start date | May 1, 2002 |
| Completion | Aug 1, 2004 |
| First posted | Aug 1, 2002 |
| Last update posted | Mar 5, 2015 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: